At a glance: AOA-flagged ocular risks NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) Identified as a very rare but serious risk associated with semaglutide, the most prescribed GLP-1RA (Ozempic, Wegovy, Rybelsus) Up to 2 increased risk with semaglutide use After conducting risk assessment, the European Medicines Agency (EMA) calls for updated product info to list NAION as a very rare side effect Signs: Sudden, painless unilateral vision loss, visual field defect, dyschromatopsia, and optic disc swelling Discontinue GLP1RA and refer immediately if NAION is suspected Diabetic retinopathy (DR) progression In the SUSTAIN-6 trial, semaglutide users showed a higher rate of DR complications (3.0%) than placebo (1.8%) This may result from rapid HbA1c reduction, a known contributor to early DR worsening Especially concerning in patients with preexisting DR Perform a baseline dilated eye exam and follow up within 1218 months of treatment initiation Neovascular AMD A population-based study found GLP-1RA users had a 2 higher relative risk of developing wet AMD (0.2% vs 0.1%) Though absolute risk remains low, the potential impact is vision-threatening Closely monitor individuals with AMD risk factors or history Other rare events Isolated reports of: Uveitis Diplopia Optic neuropathies beyond NAION These are not yet confirmed by large-scale trials but suggest the need for comprehensive baseline evaluations
Most telehealth platforms publishing at this level of provider and pharmacy specificity are operating with a degree of accountability that generic aggregator sites cannot match
Meanwhile, as influencers on social media platforms like TikTok continue to fuel the narrative of these drugs as "miracle" weight-loss solutions, transforming treatments for serious metabolic diseases into fashionable weight-loss solutions, despite manufacturers' attempts to promote responsible use
This raises concerns about pressure to pursue medical weight loss for social acceptance and underscores the need for more inclusive workplace cultures. What challenged researchers initial expectations was the depth of internalized bias many women felt more confident speaking up and willing to pursue leadership opportunities after losing weight, she said
Both tirzepatide and semaglutide are powerful GLP-1 receptor agonists used for weight management, but they work through different biological pathways
Until drug plans join next year, CMS will launch a new Medicare payment demonstration in July
